Genome-wide association analysis of age-at-onset in Alzheimer's disease

Molecular Psychiatry

Volumn 17, Issue 12, 2012, Pages 1340-1346

  Kamboh, M I ^a   Barmada, M M ^a   Demirci, F Y ^a   Minster, R L ^a   Carrasquillo, M M ^b   Pankratz, V S ^b   Younkin, S G ^b   Saykin, A J ^c   Sweet, R A ^d   Feingold, E ^a   Dekosky, S T ^e   Lopez, O L ^d  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b MAYO CLINIC   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

age at onset; Alzheimer's disease; genome wide association study; meta analysis; single nucleotide polymorphisms

Indexed keywords

APOLIPOPROTEIN E; DCHS2 PROTEIN; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CHROMOSOME 19; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; ONSET AGE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; CADHERINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84870053102     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.135     Document Type: Article

References (32)

1. Slooter AJ, Cruts M, Kalmijn S, Hofman A, Breteler MM, Van Broeckhoven C et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 1998; 55: 964-968.
2. Seshadri S, Drachman DA, Lippa CF. Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. Arch Neurol 1995; 52: 1074-1079.
3. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41: 1094-1099.
4. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41: 1088-1093.
5. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010; 303: 1832-1840.
6. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43: 429-435.
7. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011; 43: 436-441.
8. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006; 63: 168-174.
9. Daw EW, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD et al. The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet 2000; 66: 196-204.
10. Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet 2002; 70: 985-993.
11. Kamboh MI, Minster RL, Kenney M, Ozturk A, Desai OO, Kammerer CM et al. Alpha-1-antichymotrypsin (ACT or SERPINA3) polymorphom may affect aga-at-onset and disease duration of Alzheimer's disease. Neurobiol Aging 2006; 27: 1435-1439.
12. Lambert JC, Sleegers K, González-Pérez A, Ingelsson M, Beecham GW, Hiltunen M et al. The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a metaanalysis study. J Alzheimers Dis 2010; 22: 247-255.
13. Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 2008; 83: 623-632.
14. Burns LC, Minster RL, Demirci FY, Barmada MM, Ganguli M, Lopez OL et al. Replication study of genome-wide associated SNPs with late-onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2011; 156: 507-512.
15. Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, Walker LP et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet 2009; 41: 192-198.
16. Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S et al. Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimers Dement 2010; 6: 265-273.
17. Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG et al. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement 2010; 6: 239-246.
18. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010; 74: 201-209.
19. Kamboh MI, Aston CE, Hamman RF. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. Atherosclerosis 1995; 112: 145-159.
20. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet 2007; 81: 559-575.
21. Brockwell SE, Gordon IR. A comparison of statistical methods for meta-analysis. Stat Med 2001; 20: 825-840.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
23. Höng JC, Ivanov NV, Hodor P, Xia M, Wei N, Blevins R et al. Identification of new human cadherin genes using a combination of protein motif search and gene finding methods. J Mol Biol 2004; 337: 307-317.
24. McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2011; 16: 76-85.
25. Coultas L, Terzano S, Thomas T, Voss A, Reid K, Stanley EG et al. Hrk/DP5 contributes to the apoptosis of select neuronal populations but is dispensable for haematopoietic cell apoptosis. J Cell Sci 2007; 120: 2044-2052.
26. Clark ME, Kelner GS, Turbeville LA, Boyer A, Arden KC, Maki RA. ADAMTS9, a novel member of the ADAM-TS/metallospondin gene family. Genomics 2000; 67: 343-350.
27. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008; 40: 638-645.
28. Sakai K, Tiebel O, Ljungberg MC, Sullivan M, Lee HJ, Terashima T et al. A neuronal VLDLR variant lacking the third complementtype repeat exhibits high capacity binding of apoE containing lipoproteins. Brain Res 2009; 1276: 11-21.
29. Helbecque N, Berr C, Cottel D, Fromentin-David I, Sazdovitch V, Ricolfi F et al. VLDL receptor polymorphism, cognitive impairment, and dementia. Neurology 2001; 56: 1183-1188.
30. Lachman HM, Fann CS, Bartzis M, Evgrafov OV, Rosenthal RN, Nunes EV et al. Genome-wide suggestive linkage of opioid dependence to chromosome 14q. Hum Mol Genet 2007; 16: 1327-1334.
31. Heard-Costa NL, Zillikens MC, Monda KL, Johansson A, Harris TB, Fu M et al. NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium. PLoS Genet 2009; 6: e1000539.
32. Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD et al. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: a study of the ADNI cohort. Neuroimage 2010; 53: 1051-1063.